Earnings summaries and quarterly performance for DURECT.
Research analysts who have asked questions during DURECT earnings calls.
Carl Byrnes
Northland Capital Markets
2 questions for DRRX
Also covers: ALVO, BLFS, BWAY +6 more
François Brisebois
Oppenheimer & Co. Inc.
2 questions for DRRX
Also covers: ACHV, AQST, AVDL +11 more
Wing Yip
Unspecified
2 questions for DRRX
Also covers: ABUS, ACXP, ARCT +2 more
Ed Arce
WestPark Capital
1 question for DRRX
Also covers: ABUS, AKBA, ARCT +5 more
Recent press releases and 8-K filings for DRRX.
DURECT Acquired by Bausch Health
DRRX
M&A
New Projects/Investments
- Bausch Health Companies Inc. completed its acquisition of DURECT Corporation on September 11, 2025.
- Under the terms, Bausch Health acquired all outstanding shares of DURECT for $1.75 per share in cash, representing an upfront payment of approximately $63 million. The agreement also includes potential net sales milestone payments of up to $350 million.
- The acquisition adds larsucosterol, DURECT's lead asset, to Bausch Health's hepatology pipeline. Larsucosterol has an FDA Breakthrough Therapy Designation for alcohol-associated hepatitis, and a registrational Phase 3 program is being planned.
- Following the completion of the tender offer and merger, DURECT Corporation became a wholly owned subsidiary of Bausch Health, and its common stock ceased trading on Nasdaq on September 11, 2025.
Sep 11, 2025, 12:35 PM
Quarterly earnings call transcripts for DURECT.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more